Page 48 - GTM-2-4

Global Translational Medicine The research advances in HPV integration

peptide-based vaccine in patients with refractory Drugs, 41: 284–295.
advanced non-small-cell lung cancer: A phase Ib/phase IIa https://doi.org/10.1007/s10637-023-01342-x
de-escalation study. J Clin Oncol, 41: 373–384.
125. Brun JL, Dalstein V, Leveque J, et al., 2011, Regression of high-
https://doi.org/10.1200/JCO.22.00096
grade cervical intraepithelial neoplasia with TG4001 targeted
116. Atherton MJ, Stephenson KB, Pol J, et al., 2017, Customized immunotherapy. Am J Obstet Gynecol, 204: 169.e1–e8.
viral immunotherapy for HPV-associated cancer. Cancer https://doi.org/10.1016/j.ajog.2010.09.020
Immunol Res, 5: 847–859.
126. Yi M, Zheng X, Niu M, et al., 2022, Combination strategies
https://doi.org/10.1158/2326-6066.CIR-17-0102
with PD-1/PD-L1 blockade: Current advances and future
117. Atherton MJ, Stephenson KB, Nikota JK, et al., 2018, directions. Mol Cancer, 21: 28.
Preclinical development of peptide vaccination combined https://doi.org/10.1186/s12943-021-01489-2
with oncolytic MG1-E6E7 for HPV-associated cancer.
Vaccine, 36: 2181–2192. 127. Smalley Rumfield C, Pellom ST, Morillon Ii YM, et al., 2020,
Immunomodulation to enhance the efficacy of an HPV
https://doi.org/10.1016/j.vaccine.2018.02.070
therapeutic vaccine. J Immunother Cancer, 8: e000612.
118. Lauterbach H, Schmidt S, Katchar K, et al., 2021, https://doi.org/10.1136/jitc-2020-000612
Development and characterization of a novel non-lytic
cancer immunotherapy using a recombinant arenavirus 128. Gandhapudi SK, Ward M, Bush JPC, et al., 2019, Antigen
vector platform. Front Oncol, 11: 732166. priming with enantiospecific cationic lipid nanoparticles
induces potent antitumor CTL responses through novel
https://doi.org/10.3389/fonc.2021.732166
induction of a type I IFN response. J Immunol, 202: 3524–3536.
119. Quayle SN, Girgis N, Thapa DR, et al., 2020, CUE-101, a https://doi.org/10.4049/jimmunol.1801634
novel E7-pHLA-IL2-Fc fusion protein, enhances tumor
antigen-specific T-cell activation for the treatment 129. Massarelli E, William W, Johnson F, et al., 2019, Combining
of HPV16-driven malignancies. Clin Cancer Res, 26: immune checkpoint blockade and tumor-specific vaccine
1953–1964. for patients with incurable human papillomavirus 16-related
cancer: A phase 2 clinical trial. JAMA Oncol, 5: 67–73.
https://doi.org/10.1158/1078-0432.CCR-19-3354
https://doi.org/10.1001/jamaoncol.2018.4051
120. Choi CH, Choi HJ, Lee JW, et al., 2020, Phase I study of a
B cell-based and monocyte-based immunotherapeutic 130. Sousa LG, Rajapakshe K, Rodriguez Canales J, et al., 2022,
vaccine, BVAC-C in human papillomavirus type 16- or ISA101 and nivolumab for HPV-16(+) cancer: Updated
18-positive recurrent cervical cancer. J Clin Med, 9: 147. clinical efficacy and immune correlates of response.
J Immunother Cancer, 10: e004232.
https://doi.org/10.3390/jcm9010147
https://doi.org/10.1136/jitc-2021-004232
121. Karkada M, Quinton T, Blackman R, et al., 2013, Tumor
nd
inhibition by depovax-based cancer vaccine is accompanied 131. Pellom ST, Smalley Rumfield C, Morillon YM 2 , et al., 2021,
by reduced regulatory/suppressor cell proliferation and Characterization of recombinant gorilla adenovirus HPV
tumor infiltration. ISRN Oncol, 2013: 753427. therapeutic vaccine PRGN-2009. JCI Insight, 6: e141912.
https://doi.org/10.1155/2013/753427 https://doi.org/10.1172/jci.insight.141912
122. Voskens CJ, Sewell D, Hertzano R, et al., 2012, Induction 132. Aggarwal C, Saba NF, Algazi A, et al., 2023, Safety and
of MAGE-A3 and HPV-16 immunity by Trojan vaccines efficacy of MEDI0457 plus durvalumab in patients with
in patients with head and neck carcinoma. Head Neck, human papillomavirus-associated recurrent/metastatic
34: 1734–1746. head and neck squamous cell carcinoma. Clin Cancer Res,
29: 560–570.
https://doi.org/10.1002/hed.22004
https://doi.org/10.1158/1078-0432.CCR-22-1987
123. Jimeno A, Baranda JC, Mita MM, et al., 2021, Initial results
of a first-in-human, dose escalation study of a cell-based 133. Youn JW, Hur SY, Woo JW, et al., 2020, Pembrolizumab plus
vaccine in HLA A*02+ patients (pts) with recurrent, locally GX-188E therapeutic DNA vaccine in patients with HPV-
advanced or metastatic HPV16+ solid tumors: SQZ-PBMC- 16-positive or HPV-18-positive advanced cervical cancer:
HPV-101. J Clin Oncol, 39: 2536–2536. Interim results of a single-arm, phase 2 trial. Lancet Oncol,
21: 1653–1660.
https://doi.org/10.1200/JCO.2021.39.15_suppl.2536
https://doi.org/10.1016/S1470-2045(20)30486-1
124. Jimeno A, Baranda J, Iams WT, et al., 2023, Phase 1 study
to determine the safety and dosing of autologous PBMCs 134. Kim MY, Jayasinghe R, Devenport JM, et al., 2022, A
modified to present HPV16 antigens (SQZ-PBMC-HPV) in long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T
HLA-A*02+ patients with HPV16+ solid tumors. Invest New cell expansion, persistence, and anti-tumor activity. Nat

Volume 2 Issue 4 (2023) 22 https://doi.org/10.36922/gtm.2034